FENC FINANCIAL STATEMENTS

Fennec Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

FENCFennec Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue51 M $+65.0%

Gross Profit47 M $+68.6%

Operating Income-5.6 M $—

EBITDA-6.7 M $—

Net Income-8.4 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
FENC	65.0%	92.2%	-13.1%	-16.4%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
FENC	65.0%	92.2%	-13.1%	-16.4%
VNDA	8.2%	92.5%	-62.6%	-110.0%
FHTX	20.1%	22.3%	-257.0%	-266.9%
ALT	80.0%	-41,519.4%	-245,200.0%	-253,002.8%
AVIR	-100.0%	—	—	—
CABA	-100.0%	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity37.7 M $52%
Current Liabilities9.6 M $13%
Long-term Liabilities24.6 M $34%

Key Figures

YoY change

Total Assets71.8 M $+54.8%

Total Liabilities34.1 M $-34.7%

Total Equity37.7 M $—

Cash & ST Investments40.2 M $+77.2%

Total Debt——

Net Debt-40.2 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
FENC	6.98	—	—	52.5%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
FENC	6.98	—	—	52.5%
VNDA	2.16	4.7%	1.39	64.8%
FHTX	2.92	-55.0%	1.97	-34.4%
ALT	29.56	12.6%	3.35	84.6%
AVIR	7.89	0.3%	1.42	87.5%
CABA	2.95	25.6%	0.53	69.7%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-5.8 M $—

Capital Expenditures1 $-85.2%

Free Cash Flow-5.8 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
FENC	-11.3%	-11.3%	0.0%	69.0%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
FENC	-11.3%	-11.3%	0.0%	69.0%
VNDA	-58.1%	-58.5%	0.4%	52.8%
FHTX	-309.7%	-309.7%	0.1%	116.0%
ALT	-198,991.7%	-199,080.6%	88.9%	78.7%
AVIR	—	—	—	87.2%
CABA	—	—	—	81.4%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on FENC

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.